Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopamine D2 Receptor Occupancy in Patients with Schizophrenia Treated with DSP-5423P Using PET
jRCT2080221869Phase 2
- Sponsor
- Sumitomo Pharma
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Blonanserin transdermal patch in schizophrenia (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Dopamine D2 receptor occupancy by DSP-5423P.
02
Drugs
Blonanserin transdermal patch
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080221869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221869.